郭炳辰,涂应锋,于波

• 1:哈尔滨医科大学附属第二医院心内科

摘要(Abstract)：

动脉粥样硬化血栓的形成,往往会导致急性冠状动脉事件或缺血性卒中的发生,从而危及生命,因此动脉粥样硬化血栓的早期识别和诊断尤为重要。动脉粥样硬化血栓的临床诊断主要依据多种影像学检查,血管造影或血管超声等技术能准确反映血管狭窄程度,然而对早期血栓诊断仍缺乏特异性和敏感性,不能轻易检测出早期血栓或无法提供有关血栓成分的分子和细胞信息。加之动脉粥样硬化血栓患者的早期症状一般较隐匿,临床不易察觉,在血栓得到确诊时,受累器官或组织已发生器质性不可逆的损伤,故临床上迄今尚缺乏早期、特异的诊断方法。近年来,分子成像和非分子成像研究日趋深入,并得到广泛应用,分子成像和非分子成像在动脉粥样硬化血栓的早期识别和诊断的价值不断提高。本文对动脉粥样硬化血栓的成像研究进展进行了综述。

关键词(KeyWords)： 动脉粥样硬化;血栓;分子成像;非分子成像

Abstract:

Keywords:

基金项目(Foundation): 国家重点研发计划资助项目（2016YFC1301100）;; 国家自然科学基金目（81827806）

作者(Author): 郭炳辰,涂应锋,于波

参考文献(References)：

• [1] Weissleder R, Mahmood U. Molecular imaging. Radiology, 2001,219(2):316-333.
• [2] Qiao R, Huang X, Qin Y, et al. Recent advances in molecular imaging of atherosclerotic plaques and thrombosis. Nanoscale,2020, 12(15):8040-8064.
• [3] Frinking P, Segers T, Luan Y, et al. Three decades of ultrasound contrast agents:a review of the past, present and f uture improvements. Ultrasound Med Biol, 2020, 46(4):892-908.
• [4] Abou-Elkacem L, Wang H, Chowdhury SM, et al. Thy1-targeted microbubbles for ultrasound molecular imaging of pancreatic ductal adenocarcinoma. Clin Cancer Res, 2018, 24(7):1574-1585.
• [5] Wang X, Gkanatsas Y, Palasubramaniam J, et al. Thrombustargeted theranostic microbubbles:a new technology towards concurrent rapid ultrasound diagnosis and bleeding-free fibrinolytic treatment of thrombosis. Theranostics, 2016, 6(5):726-738.
• [6] Günther F, Heidt T, Kramer M, et al. Dual targeting improves capture of ultrasound microbubbles towards activated platelets but yields no additional benefit for imaging of arterial thrombosis. Sci Rep, 2017, 7(1):14898.
• [7] Ozawa K, Lindner JR. Ultrasound molecular imaging:insights into cardiovascular pathology. J Echocardiogr, 2020, 18(2):86-93.
• [8] Wu Weilan, Wang Yan, Shen Shuxin, et al. In vivo ultrasound molecular imaging of inflammatory thrombosis in arteries with cyclic Arg-Gly-Asp-modified microbubbles targeted to glycoprotein IIb/IIIa.Invest Radiol, 2013, 48(11):803-812.
• [9] Rojas JD, Dayton PA. In vivo molecular imaging using low-boilingpoint phase-change contrast agents:a proof of concept study.Ultrasound Med Biol, 2019, 45(1):177-191.
• [10] Klink A, Lancelot E, Ballet S, et al. Magnetic resonance molecular imaging of thrombosis in an arachidonic acid mouse model using an activated platelet targeted probe. Arterioscler Thromb Vasc Biol,2010, 30(3):403-410.
• [11] Zhang Y, Zhou J, Guo D, et al. Preparation and characterization of gadolinium-loaded PLGA particles surface modified with RGDS for the detection of thrombus. Int J Nanomedicine, 2013, 8:3745-3756.
• [12] Onuki Y, Jacobs I, Artemov D, et al. Noninvasive visualization of in vivo release and intratumoral distribution of surrogate MR contrast agent using the dual MR contrast technique. Biomaterials,2010, 31(27):7132-7138.
• [13] Ao M, Wang Z, Ran H, et al. Gd-DTPA-loaded PLGA microbubbles as both ultrasound contrast agent and MRI contrast agent–a feasibility research. J Biomed Mater Res B Appl Biomater, 2010, 93(2):551-556.
• [14] Liu Jia, Xu Jie, Zhou Jun, et al. FeO-based PLGA nanoparticles as MR contrast agents for the detection of thrombosis. Int J Nanomedicine, 2017, 12:1113-1126.
• [15] Myerson J, He L, Lanza G, et al. Thrombin-inhibiting perfluorocarbon nanoparticles provide a novel strategy for the treatment and magnetic resonance imaging of acute thrombosis. J Thromb Haemost, 2011, 9(7):1292-1300.
• [16] Myerson JW, He L, Allen JS, et al. Thrombin-inhibiting nanoparticles rapidly constitute versatile and detectable anticlotting surfaces. Nanotechnology, 2014, 25(39):395101.
• [17] Zhang Y, Zhong Y, Ye M, et al. Polydopamine-modified dualligand nanoparticles as highly effective and targeted magnetic resonance/photoacoustic dual-modality thrombus imaging agents. Int J Nanomedicine, 2019, 14:7155-7171.
• [18] Palekar RU, Jallouk AP, Lanza GM, et al. Molecular imaging of atherosclerosis with nanoparticle-based fluorinated MRI contrast agents. Nanomedicine(Lond), 2015, 10(11):1817-1832.
• [19] Senders ML, Que X, Cho YS, et al. PET/MR imaging of malondialdehyde-acetaldehyde epitopes with a human antibody detects clinically relevant atherothrombosis. J Am Coll Cardiol,2018, 71(3):321-335.
• [20] Andrews JPM, Portal C, Walton T, et al. Non-invasive in vivo imaging of acute thrombosis:development of a novel factor XIIIa radiotracer. Eur Heart J Cardiovasc Imaging, 2020, 21(6):673-682.
• [21] Lohrke J, Siebeneicher H, Berger M, et al. 18F-GP1, a novel PET tracer designed for high-sensitivity, low-background detection of thrombi. J Nucl Med, 2017, 58(7):1094-1099.
• [22] Chae SY, Kwon TW, Jin S, et al. A phase 1，first-in-human study of F-GP1 positron emission tomography for imaging acute arterial thrombosis. EJNMMI Res, 2019, 9(1):3.
• [23] Oliveira BL, Blasi F, Rietz TA, et al. Multimodal molecular imaging reveals high target uptake and specifcity of 111In-and 68Galabeled fbrin-binding probes for thrombus detection in rats. J Nucl Med, 2015, 56(10):1587-1592.
• [24] Blasi F, Oliveira BL, Rietz TA, et al. Multisite thrombus imaging and fbrin content estimation with a single whole-body PET scan in rats. Arterioscler Thromb Vasc Biol, 2015, 35(10):2114-2121.
• [25] Uppal R, Catana C, Ay I, et al. Bimodal thrombus imaging:simultaneous PET/MR imaging with a fbrin-targeted dual PET/MR probe–feasibility study in rat model. Radiology, 2011, 258(3):812-820.
• [26] Stacy MR, Sinusas AJ. Emerging imaging modalities in regenerative medicine. Curr Pathobiol Rep, 2015, 3(1):27-36.
• [27] Subramanian S, Jaff er FA, Tawakol A. Optical molecular imaging in atherosclerosis. J Nucl Cardiol, 2010, 17(1):135-144.
• [28] Lim B, Yao Y, Huang AL, et al. In vivo a unique recombinant fluoroprobe targeting activated platelets allows detection of arterial thrombosis and pulmonary embolism using a novel three-dimensional fluorescence emission computed tomography(FLECT)technology.Theranostics, 2017, 7(5):1047-1061.
• [29] Stein-Merlob AF, Hara T, McCarthy JR, et al. Atheroma susceptible to thrombosis exhibit impaired endothelial permeability in vivo as assessed by nanoparticle-based fluorescence molecular imaging. Circ Cardiovasc Imaging, 2017, 10(5):e005813.
• [30] Bonnard T, Jayapadman A, Putri JA, et al. Low-fouling and biodegradable protein-based particles for thrombus imaging. ACS Nano, 2018, 12(7):6988-6996.
• [31] Louie A. Multimodality imaging probes:design and challenges.Chem Rev, 2010, 110(5):3146-3195
• [32] Ughi GJ, Wang H, Gerbaud E, et al. Clinical characterization of coronary atherosclerosis with dual-modality OCT and near-infrared autofluorescence imaging. JACC Cardiovasc Imaging, 2016, 9(11):1304-1314.
• [33] Yang CT, Ghosh KK, Padmanabhan P, et al. PET-MR and SPECT-MR multimodality probes:development and challenges.Theranostics, 2018, 8(22):6210-6232.
• [34] Bourantas CV, R?ber L, Sakellarios A, et al. Utility of multimodality intravascular imaging and the local hemodynamic forces to predict atherosclerotic disease progression. JACC Cardiovasc Imaging, 2020,13(4):1021-1032.
• [35] Lux J, Vezeridis AM, Hoyt K, et al. Thrombin-activatablemicrobubbles as potential ultrasound contrast agents for the detection of acute thrombosis. ACS Appl Mater Interfaces, 2017, 9(43):37587-37596.
• [36] Tardif JC, Lesage F, Harel F, et al. Imaging biomarkers in atherosclerosis trials. Circ Cardiovasc Imaging, 2011, 4(3):319-333.
• [37] Tardif PL, Bertrand MJ, Abran M, et al. Validating intravascular imaging with serial optical coherence tomography and confocal fluorescence microscopy. Int J Mol Sci, 2016, 17(12):2110.
• [38] Sanchez OD, Sakakura K, Otsuka F, et al. Expectations and limitations of contemporary intravascular imaging:lessons learned from pathology. Expert Rev Cardiovasc Ther, 2014, 12(5):601-611.
• [39] Li J, Ma T, Mohar D, et al. Ultrafast optical-ultrasonic system and miniaturized catheter for imaging and characterizing atherosclerotic plaques in vivo. Sci Rep, 2015, 5:18406.
• [40] Li J, Ma T, Jing J, et al. Miniature optical coherence tomographyultrasound probe for automatically coregistered three-dimensional intracoronary imaging with real-time display. J Biomed Opt, 2013,18(10):100502.
• [41] Ono M, Kawashima H, Hara H, et al. Advances in IVUS/OCT and future clinical perspective of novel hybrid catheter system in coronary imaging. Front Cardiovasc Med, 2020, 7:119.
• [42] Wang T, McElroy A, Halaney D, et al. Dual-modality fiber-based OCT-TPL imaging system for simultaneous microstructural and molecular analysis of atherosclerotic plaques. Biomed Opt Express,2015, 6(5):1665-1678.
• [43] Tearney GJ, Regar E, Akasaka T, et al. Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies:a report from the international working group for intravascular optical coherence tomography standardization and validation. J Am Coll Cardiol, 2012, 59(12):1058-1072.
• [44] Hou J, Xing L, Jia H, et al. Comparison of intensive versus moderate lipid-lowering therapy on fibrous cap and atheroma volume of coronary lipid-rich plaque using serial optical coherence tomography and intravascular ultrasound imaging. Am J Cardiol,2016, 117(5):800-806.
• [45] Kubo T, Akasaka T, Shite J, et al. OCT compared with IVUS in a coronary lesion assessment:the OPUS-CLASS study. JACC Cardiovasc Imaging, 2013, 6(10):1095-1104.
• [46] Taruya A, Tanaka A, Nishiguchi T, et al. Lesion characteristics and prognosis of acute coronary syndrome without angiographically significant coronary artery stenosis. Eur Heart J Cardiovasc Imaging,2020, 21(2):202-209.
• [47] Johnson TW, R?ber L, Di Mario C, et al. Clinical use of intracoronary imaging. Part 2:acute coronary syndromes,ambiguous coronary angiography f indings, and guiding interventional decisionmaking:an expert consensus document of the European Association of Percutaneous Cardiovascular Interventions.Eur Heart J, 2019, 40(31):2566-2584.
• [48] Negishi Y, Ishii H, Suzuki S, et al. The combination assessment of lipid pool and thrombus by optical coherence tomography can predict the filter no-reflow in primary PCI for ST elevated myocardial infarction. Medicine(Baltimore), 2017, 96(50):e9297.
• [49] Kaivosoja TP, Liu S, Dijkstra J, et al. Comparison of visual assessment and computer image analysis of intracoronary thrombus type by optical coherence tomography. PLoS One, 2018, 13(12):e0209110.
• [50] Kajander OA, Koistinen LS, Eskola M, et al. Feasibility and repeatability of optical coherence tomography measurements of prestent thrombus burden in patients with STEMI treated with primary PCI. Eur Heart J Cardiovasc Imaging, 2014, 16(1):96-107.
• [51] January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation:a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the Heart Rhythm Society. J Am Coll Cardiol, 2014, 64(21):e1-e76.
• [52] Romero J, Husain SA, Kelesidis I, et al. Detection of left atrial appendage thrombus by cardiac computed tomography in patients with atrialfibrillation:a meta-analysis. Circ Cardiovasc Imaging,2013, 6(2):185-194.
• [53] Hur J, Kim YJ, Lee HJ, et al. Cardioembolic stroke:dual-energy cardiac CT for diff erentiation of left atrial appendage thrombus and circulatory stasis. Radiology, 2012, 263(3):688-695.
• [54] Du X,Wang Y. The diagnostic e fficacy of cardiac CTA combined with D-dimer assay for the detection of left atrial thrombus in patients with atrial fibrillation. Am J Emerg Med, 2019, 37(10):1922-1926.
• [55] Andrews JPM, Fayad ZA, Dweck MR. New methods to image unstable atherosclerotic plaques. Atherosclerosis, 2018, 272:118-128.
• [56] Kato S, Kitagawa K, Ishida N, et al. Assessment of coronary artery disease using magnetic resonance coronary angiography:a national multicenter trial. J Am Coll Cardiol, 2010, 56(12):983-991.
• [57] Hajhosseiny R, Bahaei TS, Prieto C, et al. Molecular and nonmolecular magnetic resonance coronary and carotid imaging.Arterioscler Thromb Vasc Biol, 2019, 39(4):569-582.
• [58] Barba I, del Blanco BG, Abdul-Jawad O, et al. MRI discriminates thrombus composition and ST resolution after percutaneous coronary intervention in patients with ST-elevation myocardial infarction.PLo S One, 2011, 6(4):e18459.
• [59] Li C, Hu A, Haacke M, et al. Direct portal vein thrombosis visualization with t2*--weighted magnetic resonance imaging. Int J Med Sci, 2013, 10(11):1570-1574.
• [60] Wahsner J, Gale EM, Rodríguez-Rodríguez A, et al. Chemistry of MRI contrast agents:current challenges and new frontiers. Chem Rev, 2019, 119(2):957-1057.
• [61] Tomaniak M, Katagiri Y, Modolo R, et al. Vulnerable plaques and patients:state-of-the-art. Eur Heart J, 2020, 41(31):2997-3004.
• [62] Zhang Y, Zhong Y, Ye M, et al. Polydopamine-modified dualligand nanoparticles as highly effective and targeted magnetic resonance/photoacoustic dual-modality thrombus imaging agents. Int J Nanomedicine, 2019, 14:7155-7171.
• [63] Thygesen K, Alpert JS, Jaff e AS, et al. Third universal definition of myocardial infarction. Circulation, 2012, 60(16):2020-2035.
• [64] Amraotkar AR, Ghafghazi S, Trainor PJ, et al. Presence of multiple coronary angiographic characteristics for the diagnosis of acute coronary thrombus. Cardiol J, 2017, 24(1):25-34.
• [65] Jaff e R, Irfan A, Hong T, et al. Intraluminal filling defects on coronary angiography:more than meets the eye. Clin Cardiol,2007, 30(9):480-484.
• [66] Savastano LE, Seibel EJ. Scanning fiber angioscopy:a multimodal intravascular imaging platf orm f or carotid atherosclerosis.Neurosurgery, 2017, 64(CN_suppl_1):188-198.